MENU
About
Our Story
Community
Diversity and Inclusion
Service Delivery
Women
Alumni
News
Offices
Toronto
New York
Calgary
Montréal
Halifax
People
X
{{letter}}
{{letter}}
Advanced Search
{{person.name}}
{{person.title}}
{{person.location}}
No results were found.
Expertise
X
Services
Banking and Debt Finance
Board Advisory and Governance
Capital Markets
Competition and Foreign Investment
Consumer Protection
Corporate Restructuring and Advisory
Data Governance and Strategy
Emerging Companies and VC
Environmental
Indigenous
Intellectual Property
Litigation and Dispute Resolution
Mergers and Acquisitions
Pensions and Employment
Private Client Services
Private Equity
Projects
Regulatory
Tax
Technology Contracting
White Collar Defence and Investigations
Industries
Agribusiness
Cannabis
Financial Services
Government
Industrial and Manufacturing
Infrastructure
Life Sciences
Media and Communications
Mining and Metals
Oil and Gas
Power
Real Estate
Retail and Consumer Products
Technology
Regions
Torys Global
Asia Pacific
Canada and the United States
Northern Canada
Europe and the United Kingdom
Latin America
Middle East and Africa
Explore Our Work
Projects Map
Insights
X
Torys Quarterly
Publications
Events
UniversiTorys
Subscribe
Trends
Torys podcasts
Securities Defence Case Comments
Transaction Tips
Business Law Guides
Trends in M&A
Shareholder Activism
Careers
X
Careers at Torys
Overview
Current Opportunities
Student Program
Lawyers
Law Clerks and Paralegals
Firm Administration
Legal Secretarial Support
Doing a Deal with Pharma
May/June 2011
Eileen M. McMahon
Cheryl V. Reicin
Print
Share
Email
LinkedIn
Twitter
Facebook
Google +
PDF
Eileen M. McMahon
Cheryl V. Reicin
Tags:
Life Sciences
Pharmaceuticals
Related Expertise
Life Sciences
Pharmaceuticals
Related Insights
Video: Navigating (and challenging) a changing life sciences regulatory environment
COVID-19 triggers Canadian intellectual property deadline extensions until August 31, 2020
Drug pricing and reimbursement: Canada
Indirect comparisons to an innovative drug’s data can trigger data protection provisions
Health Canada instructed to reconsider scope of CSP protection for drug containing multiple active ingredients
Subscribe
Back
People
Expertise
Services
Banking and Debt Finance
Board Advisory and Governance
Capital Markets
Competition and Foreign Investment
Consumer Protection
Corporate Restructuring and Advisory
Data Governance and Strategy
Emerging Companies and VC
Environmental
Indigenous
Intellectual Property
Litigation and Dispute Resolution
Mergers and Acquisitions
Pensions and Employment
Private Client Services
Private Equity
Projects
Regulatory
Tax
Technology Contracting
White Collar Defence and Investigations
Industries
Agribusiness
Cannabis
Financial Services
Government
Industrial and Manufacturing
Infrastructure
Life Sciences
Media and Communications
Mining and Metals
Oil and Gas
Power
Real Estate
Retail and Consumer Products
Technology
Regions
Torys Global
Asia Pacific
Canada and the United States
Northern Canada
Europe and the United Kingdom
Latin America
Middle East and Africa
Explore Our Work
Projects Map
Insights
Torys Quarterly
Publications
Events
UniversiTorys
Subscribe
Trends
Torys podcasts
Securities Defence Case Comments
Transaction Tips
Business Law Guides
Trends in M&A
Shareholder Activism
Careers
Overview
Current Opportunities
Student Program
Lawyers
Law Clerks and Paralegals
Firm Administration
Legal Secretarial Support
About
Our Story
Community
Diversity and Inclusion
Service Delivery
Women
Alumni
News
Offices
Toronto
New York
Calgary
Montréal
Halifax
